Vera Therapeutics (VERA) AI Stock Analysis

• Market Cap: $3.21B
• Dividend Yield: N/A
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: N/A
• EPS Growth: -53.44%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.39
• Shares Outstanding: 71,355,670
• 10 Day Avg. Volume: 1,296,162
• 30 Day Avg. Volume: 1,309,932
• PEG Ratio: -0.16
• Price to Book (P/B): 5.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.46
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -10.06
• 1Y Price Target: $83.50
• Price Target Upside: 91.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -5.26
• Revenue Forecast (FY): $42.55M

• Rating: 56 Neutral
• Price Target: $46.00 ▲(5.24% Upside)
• Action: Reiterated Date: 04/11/26
• Date: Action: Reiterated 04/11/26

The score is held back primarily by weak financial performance: pre-revenue status with rapidly rising losses and increasing cash burn, which increases funding risk despite a relatively solid, low-leverage balance sheet. Technicals are a positive offset with the stock trading above key moving averages and supportive momentum. Valuation contributes only modestly because the negative P/E is not very informative for an unprofitable company and no dividend yield is provided.

Positive Factors

Low leverage / strong capitalization

A sizable equity base and very low reported leverage provide durable financial flexibility versus high-debt peers. This reduces near-term refinancing risk, gives the company optionality to fund clinical development or pursue partnerships, and supports multi-stage R&D spending.

Negative Factors

Pre-revenue with widening losses

Sustained pre-revenue status combined with materially widening net losses erodes reserves and returns. Over the medium term this increases dependence on external capital, risks dilution, and pressures management to prioritize programs or slow development if funding conditions tighten.

Vera Therapeutics Business Overview & Revenue Model

Company Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein ...

Read more

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein ...

How the Company Makes Money

As a clinical-stage biotechnology company, Vera Therapeutics has not commercialized a product and has historically not generated product sales revenue; accordingly, recurring operating revenue from marketed drugs is null. The company’s funding to ...

Read more

As a clinical-stage biotechnology company, Vera Therapeutics has not commercialized a product and has historically not generated product sales revenue; accordingly, recurring operating revenue from marketed drugs is null. The company’s funding to ...

Vera Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-468.00K	0.00	0.00	846.00K	0.00
EBITDA	-291.62M	-144.42M	-92.18M	-88.91M	-32.41M
Net Income	-299.62M	-152.15M	-95.99M	-89.06M	-32.61M
Balance Sheet
Total Assets	734.73M	655.68M	175.55M	131.44M	83.75M
Cash, Cash Equivalents and Short-Term Investments	714.59M	640.85M	160.72M	114.65M	79.67M
Total Debt	77.31M	54.64M	53.71M	31.29M	4.92M
Total Liabilities	130.21M	78.53M	73.86M	54.53M	14.16M
Stockholders Equity	604.52M	577.15M	101.69M	76.91M	69.59M
Cash Flow
Free Cash Flow	-241.73M	-135.65M	-92.24M	-67.66M	-23.71M
Operating Cash Flow	-241.10M	-134.68M	-92.18M	-67.60M	-23.71M
Investing Cash Flow	194.29M	-425.03M	-39.43M	-70.55M	-4.20M
Financing Cash Flow	308.90M	606.67M	133.54M	101.93M	53.88M

Vera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Positive. The current price of 43.71 is above the 20-day moving average (MA) of 40.69, above the 50-day MA of 41.32, and above the 200-day MA of 34.02, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 61.70 is Neutral, neither overbought nor oversold. The STOCH value of 69.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERA.

Vera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EWTX	61 Neutral	$3.63B	-12.72	-31.97%	―	―	-5.73%
PHVS	57 Neutral	$1.79B	-7.95	-70.76%	―	―	-20.08%
VERA	56 Neutral	$3.21B	―	-59.72%	―	―	-53.44%
VRDN	54 Neutral	$1.51B	-5.48	-58.44%	―	23340.07%	18.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	50 Neutral	$906.39M	-7.53	-11.55%	―	-23.37%	-42.45%
BHVN	44 Neutral	$1.52B	-1.64	-688.89%	―	―	18.76%

Vera Therapeutics Corporate Events